Group A Streptococcus spp. A disease with many faces

Dr. Kevin Stinson, PhD CIC RMCCM




MAIN

ENTRANCE




The January 2024 Experience



St.Marys GENERAL HOSPITAL

Source: PHO iGAS Surveillance Report





Dr. Ignaz Semmelweis


World War I

Why is GAS such an effective pathogen?




What is GAS?

- Streptococcus pyogenes Gram-positive betahaemolytic cocci
- Remains a top-10 ID cause or mortality on a global front
- Colonization rates: 5% healthy adults; 20-60% school-aged children; >25% adults with household exposure



Range of colonization and illness






Virulence factors

Capsule (hyaluronic acid) T, R proteins Polysaccharide N-acetyl glucosamine N-acetyl galactosamine rhamnose, glucose, galactose (group-specific antigens) Fimbriae (M protein) Teichoic acid Lipoteichoic acid Streptolysin O enzyme \triangle DNase enzyme Hyaluronidase enzyme Streptokinase enzyme Peptidoglycan N-acetyl glucosamine N-acetyl muramic acid

- M Protein (emm gene)
- Hyaluronic Acid Capsule
- Secreted Enzymes
- Superantigens/exotoxins



Antigenic Diversity



Why have we seen a surge of iGAS?



Caution: Speculation Ahead!

Is this a hypervirulent strain?

Most commonly reported <i>emm</i> type by rank	Current season: ≥ 18 years of age (October 1, 2023 – March 31, 2024)	Previous season: ≥ 18 years of age (October 1, 2022 – March 31, 2023)	Current season: < 18 years of age (October 1, 2023 – March 31, 2024)	Previous season: < 18 years of age (October 1, 2022 – March 31, 2023)
emm1	213 (34.4%)	37 (7.7%)	68 (71.6%)	24 (40.7%)
emm80	38 (6.1%)	40 (8.3%)	0 (0.0%)	0 (0.0%)
emm12	37 (6.0%)	55 (11.4%)	9 (9.5%)	23 (39.0%)
emm82	33 (5.3%)	58 (12.0%)	0 (0.0%)	0 (0.0%)
emm59	32 (5.2%)	7 (1.4%)	0 (0.0%)	0 (0.0%)
emm74	31 (5.0%)	22 (4.6%)	0 (0.0%)	0 (0.0%)
emm49	28 (4.5%)	67 (13.9%)	1 (1.1%)	3 (5.1%)
emm41	27 (4.4%)	15 (3.1%)	0 (0.0%)	1 (1.7%)
emm92	23 (3.7%)	14 (2.9%)	0 (0.0%)	0 (0.0%)
emm2	22 (3.5%)	5 (1.0%)	4 (4.2%)	2 (3.4%)
emm76	16 (2.6%)	10 (2.1%)	0 (0.0%)	1 (1.7%)
emm28	14 (2.3%)	11 (2.3%)	1 (1.1%)	2 (3.4%)
Other	106 (17.1%)	142 (29.4%)	12 (12.6%)	3 (5.1%)
Total with emm type	620 (60.0%)	483 (75.5%)	95 (63.3%)	59 (73.8%)
Total without emm type	413 (40.0%)	157 (24.5%)	55 (36.7%)	21 (26.3%)
Total	1,033 (100.0%)	640 (100.0%)	150 (100.0%)	80 (100.0%)

Data source: iPHIS


* Cases with an unknown age are excluded from this table.

**For the previous season, only data for confirmed iGAS cases reported October 1, 2022 – March 31, 2023 are presented for comparability to the current iGAS season.



Source: PHO iGAS Surveillance Report


Loss of mucosal immunity?





Surveillance Week



FluWatch: 2019 versus 2022







Possible mechanisms

Waning IgA at mucosal surfaces allow for more efficient GAS adherence and colonization

Increased frequency and duration of viral illness increases secretions and impairs GAS clearance

Immune suppression due to repeat viral illness increases risk of secondary infection

IPAC Management of iGAS



Definition of iGAS

 GAS identified from a normally sterile site (Blood, CSF, Joint, etc.)

<u>OR</u>

- GAS identified from a non-sterile wite with evidence of severity
 - STSS with multi-organ dysfunction
 - Soft-tissue necrosis
 - Meningitis
 - Death



IPAC Precautions

Droplet Contact Precautions

Discontinue precautions after 24 hours of effective antimicrobial therapy





References

History of GAS

 Demon under the Microscope, Thomas Hager

GAS Epidemiology

- doi.org/10.1038/s41579-023-00865-7
- doi.org/10.1097/INF.000000000004111
- doi.org/10.1017/S0950268818002285
- doi.org/10.1128/jcm.00301-15
- doi.org/10.1186/1471-2180-8-59
- doi.org/10.1016/S1473-3099(09)70178-1

GAS Pathobiology

- doi.org/10.1128/msphere.00806-19
- doi.org/10.1016/j.tim.2010.02.007
- doi.org/10.1038/s41541-022-00593-8
- doi.org/10.1038/s41588-019-0417-8
- doi.org/10.1111/irv.12658
- doi.org/10.3389/fmicb.2016.00342
- doi.org/10.1093/ofid/ofad188



Questions?

kstinson@smgh.ca

